Very few commercial drug companies focus on hearing disorders. Even fewer focus on tinnitus. Otonomy does both. In this exclusive interview, we took a deep dive with Otonomy’s executives into their drug pipeline.
We spoke to David Weber (PhD), President and CEO, and Alan Foster (PhD), Chief Scientific Officer. They shared their views on what they see as the “renaissance” of hearing research and how there is currently more investor appetite to address hearing issues. We discussed why Otonomy is not only seeking solutions for different kinds of hearing loss, but also tinnitus specifically.
The interview covers each of the company’s drugs in-depth, from its mechanism of action to commercialization plans. Tinnitus drug OTO-313 targets overexcitation of the auditory nerve, which is theorized to cause tinnitus. Which types of tinnitus will benefit remains an open question, but the tinnitus community will no doubt follow the drug’s future with keen interest.
Visit https://moretinnitustalk.com to become our Patron! Your support is our lifeline. As a Patron, you will get video versions of our interviews, early access to episodes, and other perks.